AOTI, Inc. (AOTI) AI Stock Analysis

• Market Cap: £37.23M
• Dividend Yield: N/A
• Average Volume (3M): 36.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: 29.20%
• EPS Growth: 78.32%
• Country: UK
• Employees: 85
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Specialties
• EPS (TTM): 0.00
• Shares Outstanding: 106,359,160
• 10 Day Avg. Volume: 30,736
• 30 Day Avg. Volume: 36,392
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: 34.00p ▼(-2.86% Downside)

AOTI, Inc.'s stock score is primarily impacted by its financial performance, which shows revenue growth but also significant profitability and cash flow challenges. Technical analysis indicates bearish momentum, and the valuation is weak due to a negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.

AOTI, Inc. Business Overview & Revenue Model

Company Description

AOTI, Inc. engages in the development and sale of medical solutions for chronic wounds. Its products include the Topical Wound Oxygen (TWO2) Therapy and the NEXA NPWT (negative pressure wound therapy) System. The company was founded by Michael Stephen Griffiths in 2006 and is headquartered in Oceanside, CA.

How the Company Makes Money

AOTI generates revenue through multiple streams, including the sale of its proprietary optical systems and imaging software to healthcare providers, research institutions, and industrial clients. The company also engages in ongoing service contracts and maintenance agreements, which provide a steady income from existing customers. Additionally, AOTI has established strategic partnerships with key players in the healthcare and technology sectors, allowing for collaborative product development and expanded market reach. These partnerships contribute significantly to its earnings by creating synergies and enhancing its competitive position in the optical technology market.

AOTI, Inc. Financial Statement Overview

Summary

The company shows promising revenue growth and improved operational efficiency, but faces significant challenges with profitability and cash flow sustainability. High leverage and liquidity concerns remain risks despite a stronger capital structure.

Income Statement

AOTI, Inc. has shown significant revenue growth from 2021 to 2024, with a remarkable increase in gross profit margin from 5.1% in 2021 to 88.0% in 2024. However, the company remains unprofitable, with net profit margins consistently negative. EBIT and EBITDA margins improved in 2024, indicating better operational efficiency, but the persistence of net losses suggests underlying challenges in achieving profitability.

Balance Sheet

The balance sheet shows improvement in stockholders' equity, turning positive from a negative position in 2023. The debt-to-equity ratio decreased substantially in 2024, suggesting reduced leverage, but remains a risk factor given the company's history of high liabilities relative to equity. The equity ratio improved to 44.1% in 2024, reflecting a stronger capital structure.

Cash Flow

AOTI, Inc. has experienced volatile cash flows, with negative operating and free cash flows in 2024, despite an increase in financing activities. The company struggles to convert net income into positive cash flows, as seen in the negative operating cash flow to net income ratio, indicating liquidity issues and challenges in sustaining operations without external financing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	58.36M	43.92M	8.86M	889.10K
Gross Profit	51.35M	37.59M	2.86M	45.36K
EBITDA	2.64M	-4.28M	475.61K	3.58M
Net Income	-1.76M	-8.19M	1.74M	-86.82K
Balance Sheet
Total Assets	39.54M	21.08M	9.35M	1.51M
Cash, Cash Equivalents and Short-Term Investments	9.34M	778.48K	2.56M	220.20K
Total Debt	8.92M	12.35M	4.45M	805.51K
Total Liabilities	22.10M	26.99M	5.94M	1.25M
Stockholders Equity	17.44M	-5.91M	3.41M	258.29K
Cash Flow
Free Cash Flow	-7.85M	-2.76M	1.77M	-428.43K
Operating Cash Flow	-5.91M	-1.45M	2.77M	-46.07K
Investing Cash Flow	-1.94M	-1.59M	-1.23M	-392.10K
Financing Cash Flow	16.41M	-202.81K	648.65K	490.97K

AOTI, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 35.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AOTI, the sentiment is Negative. The current price of 35 is below the 20-day moving average (MA) of 37.83, below the 50-day MA of 44.96, and below the 200-day MA of 78.47, indicating a bearish trend. The MACD of -3.00 indicates Negative momentum. The RSI at 26.65 is Positive, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AOTI.

AOTI, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
POLN	―	£524.84M	9.92	9.23%	6.13%	82.69%	21.07%
RPI	―	£714.33M	97.16	4.60%	―	―	―
Sector *	―	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
AOTI	―	£37.23M	-26.12	-30.62%	―	29.20%	78.32%

AOTI, Inc. Corporate Events

AOTI, Inc. Strengthens Brokerage Team with New Appointment

AOTI, Inc. has appointed Panmure Liberum Limited as a Joint Corporate Broker, alongside Peel Hunt LLP, to enhance its corporate advisory and brokerage services. This strategic move is expected to strengthen AOTI’s market presence and support its growth initiatives in the medical technology sector, particularly in the area of wound healing and amputation prevention.

The most recent analyst rating on (GB:AOTI) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on AOTI, Inc. stock, see the GB:AOTI Stock Forecast page.

AOTI, Inc. Reports Strong H1 2025 Revenue Growth Amidst US Healthcare Challenges

AOTI, Inc. reported a 20.9% increase in revenue for the first half of 2025, driven by growth across all segments despite challenges in the US healthcare sector. The company achieved key validation milestones in the US, Germany, and the UK, enhancing its market position and reimbursement opportunities. AOTI is adapting to transitional market headwinds with strategic operational changes and cost containment measures, aiming for mid-teens revenue growth for the full year. The positive recommendations for its TWO2® therapy in Germany and the UK are expected to set valuable precedents for US reimbursement bodies, potentially unlocking significant revenue opportunities.

The most recent analyst rating on (GB:AOTI) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on AOTI, Inc. stock, see the GB:AOTI Stock Forecast page.

AOTI, Inc. to Release Interim Results and Host Investor Meetings

AOTI, Inc. has announced the release of its interim results for the first half of 2025, scheduled for September 22, 2025. The company will host meetings for analysts and investors to discuss these results, with opportunities for stakeholders to engage through presentations and Q&A sessions. This announcement underscores AOTI’s commitment to transparency and stakeholder engagement, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (GB:AOTI) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on AOTI, Inc. stock, see the GB:AOTI Stock Forecast page.

AOTI’s TWO2® Therapy Gains NICE Recommendation and NHS Framework Inclusion

AOTI, Inc. announced that its Topical Wound Oxygen (TWO2®) therapy is now included in the NICE guidelines for diabetic foot problems and is active on the NHS Supply Chain’s Advanced Wound Care Framework. This inclusion allows for accelerated marketing and easier access for NHS organizations, potentially improving patient outcomes and reducing healthcare costs. The recognition by NICE and the NHS framework is a significant step forward for AOTI, enhancing its market position and validating its clinical value proposition.

The most recent analyst rating on (GB:AOTI) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on AOTI, Inc. stock, see the GB:AOTI Stock Forecast page.

AOTI, Inc. Director Increases Stake with Significant Share Purchase

AOTI, Inc. announced that Richard Cotton, the Senior Independent Director, and Jane Cotton-Hall have purchased a total of 215,430 common shares, representing approximately 0.20% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, reflects confidence in the company’s market position and potential growth, potentially impacting stakeholder perceptions positively.

AOTI CFO Increases Stake with Significant Share Purchase

AOTI, Inc. announced that its Chief Financial Officer, Mr. Jayesh Pankhania, purchased a substantial number of the company’s common shares, increasing his total holdings to 405,539 shares. This transaction, conducted on the London Stock Exchange, reflects a significant personal investment in the company, potentially signaling confidence in AOTI’s market position and future prospects. The purchase was made in compliance with the Market Abuse Regulation, and it underscores the company’s commitment to transparency in its financial dealings.